1MO Tumor immune microenvironment in ER-negative vs ER-low, HER2-neg breast cancer
Davide Massa(University of Padua), Maria Vittoria Dieci(Istituto Oncologico Veneto), Riccardo Lobefaro(Fondazione IRCCS Istituto Nazionale dei Tumori), Claudio Vernieri(Fondazione IRCCS Istituto Nazionale dei Tumori), Federica Miglietta(University of Padua), G. Griguolo(University of Padua), Beatrice Taurelli Salimbeni(European Institute of Oncology), Andrea Vingiani(Istituti di Ricovero e Cura a Carattere Scientifico), Séverine Guiu(Inserm), Matteo Fassan(University of Padua), William Jacot(Inserm), V. Guarneri(University of Padua), Giancarlo Pruneri(University of Milan), Angélique Bobrie(Inserm), Carmen Criscitiello(University of Milan), Lorenzo Nicolè(University of Padua), Giuseppe Curigliano(European Institute of Oncology)
Cited by 4
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k